Abstract
Cameron Thorpe (Mayo Clinic Arizona, Phoenix, AZ, USA) presented early results from the MC1635 trial. 107 patients with localised breast cancer who had breast-conserving surgery were randomly assigned (1:1) to whole-breast radiotherapy with moderate hypofractionation (40 Gy in 15 fractions; n=54) or extreme hypofractionation (25 Gy in five fractions; n=55). At a median follow-up of 20 months, there were no grade 3 adverse effects; grade 2 adverse effects were reported in 7% of patients in each group. Average cosmesis and quality-of-life scores were similar between groups. Moderate to severe radiation skin burns were more common with moderate hypofractionation (58·7%) than with extreme hypofractionation (27·9%; odds ratio 3·7, 95% CI 1·5–8·9; p=0·004).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
